Efficacy and safety of decitabine against cutaneous granuloblastic sarcoma: a case report
Author:
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Link
http://link.springer.com/article/10.1007/s00277-018-3314-9/fulltext.html
Reference6 articles.
1. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670–2677
2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405
3. Avni B, Koren-Michowitz M (2011) Myeloid sarcoma: current approach and therapeutic options. Ther Adv Hematol 2:309–316
4. Steensma DP, Friday BB (2007) Monocytic skin nodules in chronic myelomonocytic leukemia: clinical response to decitabine therapy. Leuk Lymphoma 48(8):1628–1629
5. Singh SN, Cao Q, Gojo I, Rapoport AP, Akpek G (2012) Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT. Bone Marrow Transplant 47(7):1008–1009
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Myeloid sarcoma in JAK2-positive myelodysplastic neoplasms with fibrosis: a case report and literature review;Journal of International Medical Research;2024-08
2. Myeloid sarcoma: more and less than a distinct entity;Annals of Hematology;2023-06-07
3. Myeloid sarcoma: An overview;Seminars in Diagnostic Pathology;2023-05
4. Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine;Case Reports in Hematology;2021-04-21
5. Durable Remission of Chemotherapy-Refractory Myeloid Sarcoma by Azacitidine;The Tohoku Journal of Experimental Medicine;2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3